Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Gyre Therapeutics (GYRE) over the last 15 years, with Dec 2024 value amounting to $26.7 million.

  • Gyre Therapeutics' Cash & Current Investments rose 138.99% to $60.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.1 million, marking a year-over-year increase of 41.21%. This contributed to the annual value of $26.7 million for FY2024, which is 20.28% down from last year.
  • As of FY2024, Gyre Therapeutics' Cash & Current Investments stood at $26.7 million, which was down 20.28% from $33.5 million recorded in FY2023.
  • Gyre Therapeutics' Cash & Current Investments' 5-year high stood at $130.9 million during FY2020, with a 5-year trough of $25.2 million in FY2022.
  • Its 3-year average for Cash & Current Investments is $28.5 million, with a median of $26.7 million in 2024.
  • As far as peak fluctuations go, Gyre Therapeutics' Cash & Current Investments plummeted by 62.29% in 2021, and later spiked by 33.10% in 2023.
  • Gyre Therapeutics' Cash & Current Investments (Yearly) stood at $130.9 million in 2020, then slumped by 62.29% to $49.4 million in 2021, then crashed by 48.99% to $25.2 million in 2022, then surged by 33.10% to $33.5 million in 2023, then declined by 20.28% to $26.7 million in 2024.